Caliper Awarded New Task Order for EPA ToxCa...(that it will continue to experience stro...),Health

Date:11/9/2009

that it will continue to experience strong growth from its imaging and microfluidic products, are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including that the EPA may stop or curtail funding under its ToxCast screening program, Caliper may experience unexpected delays in its receipt of compounds from the EPA for testing under the ToxCast program, and Caliper's expectations regarding demand for its products and services may not materialize if capital spending by Caliper's customers declines, if competitors introduce new competitive products, or if Caliper is unable to convince potential customers regarding the superior performance of its drug discovery and imaging systems and other products. Further information on risks faced by Caliper are detailed under the caption "Risks Related To Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2008. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release or the conference call.

NOTE: Caliper, LabChip, and EZ Reader are registered trademarks of Caliper Life Sciences, Inc. ToxCast is a trademark of the Environmental Protection Agency.

SOURCE Caliper Life Sciences, Inc.

'/>"/>

SOURCE Caliper Life Sciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
2. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
3. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
4. Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
5. B. Braun Awarded Contract With HealthTrust Purchasing Group to Provide Pain Management Solutions
6. Noninvasive Medical Technologies Awarded ISO 13485 Quality Certification
7. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
8. SRI International Awarded National Institute of Mental Health Contract for Evaluation of Brain Imaging Agents and Medications for Treatment of Mental Disorders
9. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
10. AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis
11. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant